Joint Transnational Call 2017 (JTC2017)


Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare genetic disease (prevalence: 1 in 20 million) characterized by multiorgan defects, accelerated aging, and death at an average age of 14.6 years mainly from myocardial infarction or stroke. It is caused by a heterozygous de novo point mutation in the LMNA gene leading to the synthesis of progerin, a permanently farnesylated prelamin A mutant protein. HGPS has no cure and clinical trials targeting progerin farnesylation showed increased mean survival of only ~1.6 years in treated patients. It is therefore urgent to develop new strategies to treat or cure HGPS. 

  • Andrés, Vincente (Coordinator)
    Fundación Centro National de Investigaciones Cardiovasculares Carlos III (CNIC) [SPAIN]
  • Filgueiras, David
    Fundación Investigación Biomédica Hospital Clínico San Carlos [SPAIN]
  • Rzepecki, Ryszard
    University of Wroclaw [POLAND]
  • Lattanzi, Giovanni
    CNR Institute of Molecular Genetics [ITALY]
  • Djabali, Karima
    School of Medicine, Technical University of Munich [GERMANY]